The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused the COVID-19 pandemic, is proved to involve multiple organs and systems, primarily targeting the cardiac and respiratory system. Cardiac arrhythmia, which induces by myocardial damage and subsequent cardiac dysfunction, is a major clinical manifestation in cardiac injury. 1 Previous data revealed that 9%-16.7% of hospitalized patients with COVID-19 suffering an unspecified arrhythmic event 2,3 and contributed to 44% of those transferred to the ICU. 3 The 17.6% of primary QTc prolongation and 0.38% of secondary torsade de pointes in COVID-19 patients were disclosed by a detailed investigation. 4 In addition, other drug interventions that appear to be independent of anti-SARS-CoV-2 treatment, such as terlipressin, 5 oxaliplatin, and so forth, are increasingly at risk of arrhythmias in the COVID-19 patients with gastrointestinal (GI) bleeding.